Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Obesity: When to consider medication.

Katherine H Saunders1, Alpana P Shukla1, Leon I Igel1

  • 1Comprehensive Weight Control Center, Division of Endocrinology, Diabetes and Metabolism, Cornell Medicine, New York, NY, USA.

The Journal of Family Practice
|October 10, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial.

Lancet (London, England)·2026
Same author

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.

Nature medicine·2026
Same author

Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5.

Journal of endocrinological investigation·2026
Same author

Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide.

Obesity (Silver Spring, Md.)·2026
Same author

Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.

The American journal of medicine·2026
Same author

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.

Nature medicine·2026
Same journal

Does taking BP medicine at night (vs morning) result in fewer cardiovascular events?

The Journal of family practice·2023
Same journal

Preventing RSV in children and adults: A vaccine update.

The Journal of family practice·2023
Same journal

Essential oils: How safe? How effective?

The Journal of family practice·2023
Same journal

51-year-old woman • History of Graves disease • General fatigue, palpitations, and hand tremors • Dx?

The Journal of family practice·2023
Same journal

Renewing the dream.

The Journal of family practice·2023
Same journal

55-year-old woman • Myalgias and progressive symmetrical proximal weakness • History of unilateral renal agenesis, type 2 diabetes, and hyperlipidemia • Dx?

The Journal of family practice·2023
See all related articles

Newest weight loss drugs can be combined with diet, exercise, and behavior changes for effective obesity treatment. These integrated approaches support sustainable health outcomes.

Area of Science:

  • Pharmacology
  • Metabolic Disorders
  • Behavioral Science

Background:

  • Obesity is a complex metabolic disorder requiring multifaceted treatment strategies.
  • Pharmacological interventions are increasingly recognized as a key component of comprehensive weight management.
  • Integrating new weight loss medications with lifestyle modifications is crucial for patient success.

Observation:

  • Four distinct cases demonstrate the practical application of novel weight loss pharmacotherapies.
  • These cases highlight the synergistic effects of combining medication with diet, exercise, and behavioral therapy.
  • Patient adherence and response varied, underscoring the need for personalized treatment plans.

Findings:

  • The newest weight loss drugs, when used adjunctively, can significantly enhance weight reduction.

Related Experiment Videos

  • Successful integration requires careful patient selection and ongoing monitoring.
  • A holistic approach combining medication, nutrition, physical activity, and behavioral support yields optimal results.

    • Implications:

    • These findings suggest a paradigm shift towards personalized, pharmacologically-assisted weight management programs.
    • Clinicians can confidently incorporate the latest weight loss medications into patient care plans.
    • Further research is warranted to explore long-term efficacy and safety profiles of these integrated treatments.